June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
May 2025 in “Russian Journal of Allergy” Combining antihistamines with topical treatment improves hair regrowth in alopecia areata.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
Bempikibart may help regrow hair in people with alopecia areata.
Baricitinib is more effective than methotrexate for severe alopecia areata.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
April 2025 in “Egyptian journal of Immunology” Calprotectin levels are higher in alopecia areata patients, indicating systemic inflammation.
March 2025 in “Pakistan Journal of Health Sciences” Intralesional steroids improve Alopecia Areata, and trichoscopy effectively tracks this improvement.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
January 2025 in “The Journal of Dermatology” Certain patient traits can predict better hair regrowth with baricitinib in severe alopecia areata.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
January 2025 in “Journal of Bacha Khan Medical College.” Double-spin PRP is more effective for treating male pattern baldness.
January 2025 in “International Journal of Trichology” Combining DPCP with PRP doesn't improve hair regrowth in alopecia areata.
Human placental extract effectively and safely improves melasma, ulcers, and alopecia areata.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
January 2025 in “International Journal of Dermatology Research” Higher MPV and CRP levels may indicate more severe alopecia areata.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
January 2025 in “Figshare” Compound glycyrrhizin combined with conventional treatments effectively and safely promotes hair regrowth in alopecia areata patients.
January 2025 in “Figshare” Compound glycyrrhizin with conventional treatments is effective and safe for promoting hair regrowth in alopecia areata.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
November 2024 in “Journal of Investigative Dermatology” Certain NK cell changes in blood may indicate alopecia areata progression.